← board
MREO
distress 3/10 · well-funded / low risk$0.30+0%today-87% from 52w high
Lead: osteogenesis imperfecta
Revenue
pre-revenue
Liquidity
$36M
Runway
1.3 yrs
Shares 1y
+0%
Price & events
-43.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
-7.5%
1W
-7.2%
1M
-2.7%
3M
-43.3%
6M
-84.0%
1Y
-92.8%
2Y
-88.0%
5Y
-91.6%
All
Overview
- Market Cap
- $238.47M
- Volume
- 107.16K
- 52 Week Range
- $0.24 – $2.31
- Total Shares
- 798.09M
- Float Shares
- 117.16M
- Short %
- 4.53%
- % Held by Insiders
- 0.75%
- % Held by Institutions
- 47.90%
- RVOL
- 0.08x
- Beta
- 0.29
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2H 2026Guided 55%trial initiationsecondaryPhase 2vantictumab · Plan to initiate Phase 2 studySEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- January 14, 2026 at 1:30pm PTconferencedata presentationsecondaryJ.P. Morgan Healthcare Conference presentation with corporate updateSEC 8-K
- fourth quarter of 2025readoutPhase 3setrusumab · Potential final analysis of Phase 3 Orbit studySEC 8-K
- mid-2025readoutPhase 3setrusumab · Second interim analysis of Phase 3 Orbit studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-12BTIGBuy
- 2026-03-23JP MorganOverweight → Neutral
- 2026-01-16BTIGBuy
- 2026-01-13NeedhamBuy
- 2025-12-30JefferiesBuy → Hold
- 2025-12-29LifeSci CapitalOutperform → Market Perform
Competitors — osteogenesis imperfecta
Recent news
- 2026-06-25Mereo BioPharma (MREO) Edges Lower as Stock Tests Key Support Near $0.28 - Scalping Stock Signals - dars.gov.et
- 2026-05-25Mereo BioPharma Group plc (MREO) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock Uplift - Margin Improvement Report - dars.gov.et
- 2026-05-12Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
- 2026-05-12Mereo BioPharma Group Releases Q1 2026 Financial Results - AlphaStreet
- 2026-05-12Mereo BioPharma Group plc 1Q 2026: Net loss $(6.7M), EPS $(0.01) — 10-Q Summary - TradingView
- 2026-04-06MREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, - GlobeNewswire
- 2026-04-06Class Action Filed Against Mereo BioPharma Group plc (MREO) - GlobeNewswire
- 2026-04-03Investors in Mereo BioPharma urged to act before April 6, 2026 deadline in securities lawsuit. - Pluang
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.